Your online resource for objective IBD information
Introduction
Symptoms
Inflammatory bowel disease (IBD) includes Crohn’s disease and ulcerative colitis, both conditions causing inflammation of the intestines. IBD is the result of an exaggerated or insufficiently suppressed immune response that damages the gut wall. This damage allows toxins and bacteria to seep through the intestinal wall and into the blood stream, further accelerating the inflammatory process. Although the diseases have some features in common, there are some important differences.
Ulcerative colitis is an inflammatory disease of the large intestine, also called the colon. In ulcerative colitis only the inner lining part of the colon wall (the mucosa) becomes inflamed and develops ulcers. Ulcerative colitis is often the most severe in the rectal area, which can cause frequent diarrhoea. Mucus and blood often appear in the faeces if the lining of the colon is damaged.
Crohn’s disease is different from ulcerative colitis because it commonly affects the last part of the small intestine and parts of the large intestine, although in theory it can attack any part of the digestive tract. The inflammation associated with Crohn’s disease extends much deeper into the layers of the intestinal wall than with ulcerative colitis. Crohn’s disease generally tends to involve the entire bowel wall, whereas ulcerative colitis affects only the lining of the bowel.
Causes
Fatty acids
Heavily involved in the regulation of inflammation related to IBD are a group of hormone-like substances called prostaglandins. Prostaglandins are effectively by-products of fatty acids consumed in the diet, since specific omega-3 and omega-6 fatty acids are converted into different families of prostaglandins, being either inflammatory or anti-inflammatory. The prostaglandins produced from the omega-6 fatty acid arachidonic acid (AA), however, are considered primarily responsible for inflammatory processes and the intestinal inflammation seen in inflammatory bowel disease. If there is a higher intake of omega-3 EPA, however, this causes competition with AA for the utilisation of specific enzymes, and inhibits the production of inflammatory prostaglandins. The ability of EPA to reduce the inflammatory response indicates great potential for alleviating symptoms of inflammatory bowel disease. By combining EPA with GLA, an anti-inflammatory omega-6 fatty acid, common to all of our omega supplements, this further enhances the beneficial anti-inflammatory effects of EPA.
Recommendation
With its high EPA content we recommend Vegepa at up to 8 capsules daily for a period of 3 months. This can then be reduced down by 2 capsules weekly to a final maintenance dose of 2 capsules daily.
For children we recommend Vegepa Chewables. Children of ten and over can take up to 6 capsules daily for a period of 3 months. This can then be reduced down by 2 capsules weekly to a final maintenance dose of 2 capsules daily.
For vegetarians, our Echiomega supplement provides a more effective solution than flaxseed oil, with higher conversion to the important long-chain fatty acid EPA.
Research Articles







